Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences

Rhea-AI Summary

Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company, has announced its participation in two upcoming investor conferences. The company will be part of a panel discussion titled 'Expanding Platform Potential' at the Longwood Boston CEO Conference on October 28, 2024, at 11:10 AM ET.

Additionally, Precision BioSciences will participate in a fireside chat at the Guggenheim Inaugural Healthcare Conference on November 11, 2024, at 3:00 PM ET at the InterContinental Boston. A live webcast of this event will be available on the company's website, with an archived replay accessible for approximately 30 days after the event.

Precision BioSciences utilizes its proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits.

DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will participate in the following upcoming investor conferences.

Longwood Boston CEO Conference
Date: Monday, October 28, 2024
Time: 11:10 AM ET
Title: Expanding Platform Potential
Format: Panel

Guggenheim Inaugural Healthcare Conference
Date: Monday, November 11, 2024
Time: 3:00 PM ET
Location: InterContinental Boston
Format: Fireside Chat
Webcast Link: Register Here

A live webcast for the Guggenheim Inaugural Healthcare Conference will also be accessible on Precision’s website in the Investors section under Events & Presentations at investor.precisionbiosciences.com. An archived replay of the webcasts will be available for approximately 30 days following the event.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.

The ARCUS® platform is being used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome e.g. viral DNA or mutant mitochondrial DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single AAV).

View source version on businesswire.com: https://www.businesswire.com/news/home/20241021549147/en/

Investor and Media Contact:

Naresh Tanna

Vice President of Investor Relations

naresh.tanna@precisionbiosciences.com

Source: Precision BioSciences, Inc.

FAQ

When is Precision BioSciences (DTIL) participating in the Longwood Boston CEO Conference?

Precision BioSciences (DTIL) is participating in the Longwood Boston CEO Conference on Monday, October 28, 2024, at 11:10 AM ET.

What is the format of Precision BioSciences' (DTIL) presentation at the Guggenheim Inaugural Healthcare Conference?

Precision BioSciences (DTIL) will participate in a fireside chat format at the Guggenheim Inaugural Healthcare Conference.

Where can investors access the webcast for Precision BioSciences' (DTIL) Guggenheim Conference presentation?

Investors can access the webcast for Precision BioSciences' (DTIL) Guggenheim Conference presentation on the company's website in the Investors section under Events & Presentations at investor.precisionbiosciences.com.

What is the main focus of Precision BioSciences' (DTIL) gene editing technology?

Precision BioSciences (DTIL) focuses on developing in vivo gene editing therapies for sophisticated gene edits using their proprietary ARCUS® platform.